Gruppo Oncologico Italiano Di Ricerca Clinica

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer gr…

This study tests whether the drug avelumab can help keep metastatic urothelial carcinoma (a type of bladder cancer) from growing after patients have already received two lines of chemotherapy. About 144 adults whose cancer has not worsened after second-line chemo will receive ave…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recr…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (XELOX) after chemoradiation improves outcomes for people with locally advanced rectal cancer. About 270 participants will be randomly assigned to receive either the combination or chemoth…

This study looks at 150 adults aged 18-49 who are newly diagnosed with early-onset gastrointestinal cancer. Researchers will collect information on the cancer's features, patients' lifestyle habits, and how the disease progresses over 12 months. The goal is to better understand t…